How to appeal a Biologic / Buy-and-Bill Infusion denial
Biologic infusion denials are the highest-dollar recurring exposure in these practices, they target the J-code drug the practice already bought, step-therapy and site-of-care requirements, and the infusion-administration units.
Common code: CPT 96365-96368/96413-96417 (infusion admin) + J-codes (J1745 infliximab, J9312 rituximab, J3357 ustekinumab)Why it gets denied
- Step-therapy requires trying a preferred biologic or biosimilar first and it wasn't documented
- Prior authorization lapsed or didn't cover the dose/frequency infused
- Site-of-care policy pushed the infusion to home/facility and denied the in-office claim
- J-code drug units or infusion time units don't reconcile to the dose administered, or waste (JW) wasn't billed
What overturns it
- Document the step-therapy trial/failure or the medical reason the preferred agent is inappropriate and pursue the exception
- Keep prior auth current for the exact drug, dose, and frequency and tie it to the claim
- Appeal site-of-care denials with the clinical reason in-office infusion is required
- Reconcile drug and infusion-time units to the record and bill waste correctly with JW/JZ
Worth appealing? A single infliximab or rituximab infusion can run thousands in drug cost the practice fronts, so a denied J-code is direct capital loss. These are the most important claims to recover and are winnable with auth and dosing documentation.
Common questions
How do I appeal a Biologic / Buy-and-Bill Infusion denial?
Biologic infusion denials are the highest-dollar recurring exposure in these practices, they target the J-code drug the practice already bought, step-therapy and site-of-care requirements, and the infusion-administration units. To overturn it: document the step-therapy trial/failure or the medical reason the preferred agent is inappropriate and pursue the exception; keep prior auth current for the exact drug, dose, and frequency and tie it to the claim; appeal site-of-care denials with the clinical reason in-office infusion is required; reconcile drug and infusion-time units to the record and bill waste correctly with JW/JZ.
Why do Biologic / Buy-and-Bill Infusion claims get denied?
Step-therapy requires trying a preferred biologic or biosimilar first and it wasn't documented; Prior authorization lapsed or didn't cover the dose/frequency infused; Site-of-care policy pushed the infusion to home/facility and denied the in-office claim; J-code drug units or infusion time units don't reconcile to the dose administered, or waste (JW) wasn't billed.
Is a Biologic / Buy-and-Bill Infusion denial worth appealing?
A single infliximab or rituximab infusion can run thousands in drug cost the practice fronts, so a denied J-code is direct capital loss. These are the most important claims to recover and are winnable with auth and dosing documentation. You pay 25% only on what's recovered, so there's no cost to working the winnable ones.
See how many Biologic / Buy-and-Bill Infusion denials you wrote off.
A free assessment shows your real recoverable number. No risk, paid only on what we recover.